NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 25,132 shares of the firm's stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $25.49, for a total transaction of $640,614.68. Following the completion of the sale, the insider now owns 10,777,092 shares of the company's stock, valued at $274,708,075.08. This trade represents a 0.23 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
Nap B.V. Forgrowth also recently made the following trade(s):
- On Friday, December 20th, Nap B.V. Forgrowth sold 49,772 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.60, for a total value of $1,274,163.20.
- On Wednesday, December 18th, Nap B.V. Forgrowth sold 100,728 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $26.10, for a total value of $2,629,000.80.
- On Thursday, December 12th, Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.39, for a total value of $4,215,019.29.
- On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.08, for a total transaction of $834,486.84.
- On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.02, for a total transaction of $213,420.60.
NewAmsterdam Pharma Price Performance
AI breakthrough about to upend industry
From Porter & Company | Ad
Everyone is talking about AI right now.
The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI.
But here’s the thing.
I urge you to watch it now.
NAMS opened at $26.23 on Friday. NewAmsterdam Pharma has a one year low of $10.50 and a one year high of $27.29. The stock's fifty day moving average is $21.86 and its 200-day moving average is $19.14.
Hedge Funds Weigh In On NewAmsterdam Pharma
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Banque Cantonale Vaudoise acquired a new stake in shares of NewAmsterdam Pharma during the 2nd quarter valued at $38,000. Quarry LP increased its holdings in shares of NewAmsterdam Pharma by 2,469.2% during the 3rd quarter. Quarry LP now owns 6,500 shares of the company's stock valued at $108,000 after acquiring an additional 6,247 shares during the last quarter. Barclays PLC raised its position in shares of NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after purchasing an additional 7,199 shares during the period. Bellevue Group AG acquired a new stake in shares of NewAmsterdam Pharma in the third quarter valued at about $128,000. Finally, XTX Topco Ltd bought a new position in NewAmsterdam Pharma in the 3rd quarter worth approximately $187,000. 89.89% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the stock. Scotiabank increased their price target on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a "sector outperform" rating in a research note on Wednesday, December 11th. Royal Bank of Canada reiterated an "outperform" rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Piper Sandler restated an "overweight" rating and set a $37.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $36.20.
Read Our Latest Research Report on NAMS
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
